Relationship between response rates and median progression‐free survival in non‐Hodgkin's lymphoma: A meta‐analysis of published clinical trials
Authors:
- 14 July 2017
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 36 (1) , 37-43
Abstract
Demonstration of clinical effectiveness of a non‐Hodgkin's lymphoma (NHL) treatment generally involves determination of progression‐free survival (PFS). However, the long evaluation time of PFS limits its utility to make timely decisions in drug development. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in NHL. A database was systematically developed from 513 identified NHL trials reported from 1996 to 2015. Potential predictors of the relationship between response rates and PFS were evaluated, including age, sex, treatment, percentage of treatment‐naïve patients, and subtype of NHL. Seventy‐three trials involving 86 cohorts were included in the meta‐analysis. Linear regression analysis using logit of response rates and logarithm of median PFS indicated that the correlation between overall response rate (ORR) and median PFS was higher (R2 = 0.70) when compared to that of complete response (CR) rate and median PFS (R2 = 0.57). Furthermore, the correlation was improved with the addition of percentage of treatment‐naïve patients and percentage of patients with follicular lymphoma (FL) (P < .005) between ORR and median PFS (R2 = 0.78), and between CR rate and median PFS relationship (R2 = 0.74). Treatment was not found to alter this relationship. In summary, ORR is as good as CR rate in predicting median PFS. Moreover, longer median PFS is expected in the trials including treatment‐naïve and/or FL patients at a given ORR/CR rate. The determined relationship can be used to project the median PFS based on ORR or CR rate.Keywords
Funding Information
- AbbVie
This publication has 28 references indexed in Scilit:
- The Strength of Association Between Surrogate End Points and Survival in OncologyJAMA Internal Medicine, 2015
- Outcomes and endpoints in cancer trials: bridging the divideThe Lancet Oncology, 2015
- Outcomes and endpoints in trials of cancer treatment: the past, present, and futureThe Lancet Oncology, 2015
- Meta-analysis for the Association between Overall Survival and Progression-Free Survival in Gastrointestinal Stromal TumorClinical Cancer Research, 2014
- Endpoints in cancer clinical trialsJournal of Visceral Surgery, 2014
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012JAMA, 2014
- Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer TrialsClinical Cancer Research, 2013
- Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancerAnnals of Oncology, 2012
- Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsAnnals of Oncology, 2011
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007JNCI: Journal of the National Cancer Institute, 2010